Intracellular matrix metalloproteinase-2 (MMP-2) regulates human platelet activation via hydrolysis of talin

Thrombosis and Haemostasis

Volumn 111, Issue 1, 2013, Pages 140-153

  Soslau, Gerald ^a   Mason, Christopher ^a   Lynch, Stephen ^a   Benjamin, James ^a   Ashak, Dani ^a   Prakash, Jamunabai M ^a   Moore, Andrew ^a   Bagsiyao, Pamela ^a   Albert, Trevine ^a   Mathew, Lynn M ^a   Jost, Monika ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Matrix metalloproteinase; Platelet physiology; Talin; Thrombin

Indexed keywords

1, 10 PHENANTHROLINE; 4 (2 AMINOETHYL) BENZENESULFONYL FLUORIDE; CALPAIN; CD45 ANTIGEN; FIBRINOGEN RECEPTOR; FOCAL ADHESION KINASE INHIBITOR; GAMMA THROMBIN; GELATINASE A; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERSTITIAL COLLAGENASE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; STAT3 PROTEIN; TALIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; IMMUNOFLUORESCENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; WESTERN BLOTTING;

MATRIX METALLOPROTEINASE; PLATELET PHYSIOLOGY; TALIN; THROMBIN;

ADULT; BINDING SITES; BLOOD PLATELETS; CALPAIN; CHELATING AGENTS; DIMERIZATION; GENE EXPRESSION REGULATION; HUMANS; HYDROLYSIS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PHENANTHROLINES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TALIN; TIME FACTORS; ZINC;

EID: 84891887337     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-03-0248     Document Type: Article

References (56)

1. Hadler-Olsen E, Fadnes B, Sylte I, et al. Regulation of matrix metalloproteinases activity in health and disease. FEBS J 2011; 278: 28-45.
2. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
3. Back M, Ketelhuth DF, Agewall S. Matrix Metalloproteinases in atherothrombosis. Progress in Cardiovascular Diseases 2010; 52: 410-428.
4. Cunningham LA, Wezel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005; 50: 329-339.
5. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors or metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009; 158: 983-994.
6. Sawicki G, Salas E, Murat J, et al. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 616-619.
7. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, et al. Differential regualtion of platelet aggregation by matrix metalloproteinases-9 and-2. Thromb Haemost 1999; 82: 1730-1735.
8. Kazes I, Elalamy I, Sraer J-D, et al. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood 2000; 96: 3064-3069.
9. Galt SW, Lindemann S, Allen L, et al. Outside-In signals delivered by matrix metalloproteinase-1 to regulate platelet function. Circ Res 2002; 90: 1093-1099.
10. Falcinelli E, Gugliemini G, Torti M, et al. Intraplatelet signalling mechanisms of the matrix metalloproteinase-2 on platelet aggregation. J Thromb Haemost 2005; 3: 2526-2535.
11. Lee YM, Lee JJ, Shen MY, et al. Inhibitory mechanisms of activated matrix metalloproteinases-9 on platelet activation. Eur Pharmacol 2006; 537: 52-58.
12. Choi W S, Jeon O H, Kim H, et al. MMP-2 regulates human platelet activation by interacting with integrin (IIb(3. J Thromb Haemost 2008; 6: 517-523.
13. Santos-Martinez MJ, Medina C, Jurasz P, et al. Role of metalloproteinases in platelet function. Thromb Res 2008; 121: 535-542.
14. Santos-Martinez MJ, Medina C, Glimer JF, et al. Matrix metalloproteinases in platelet function: coming of age. J Thromb Haemost 2008; 6: 514-516.
15. Juarasz P, Chung AWY, Radomski A, et al. Nonremodelling properties properties of matrix metalloproteinases. The platelet connection. Circ Res 2002; 90: 1041-1043.
16. Sheu JR, Fong TH, Liu CM, et al. Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies. Pharmacol 2004; 143: 191-201.
17. Galt SW, Lindemann S, Allen L, et al. Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res 2002; 90: 1093-1099.
18. Falcinelli E, Bury L, Tolley N, et al. MMP-9 in platelets: maybe, maybe not. Blood 2011; 118: 6471-6473.
19. Kalvegren H, Jonsson S, Jonasson L. Release of matrix metalloproteinases-1 and-2, but not-9, from activated platelets measured by enzyme-linked immunosorbent assay. Platelets 2011; 22: 572-578.
20. Trivedi V, Boire A, Tchernychev B, et al. Platelet matrix metalloproteinase-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009; 137: 332-343.
21. Shattil SJ, Kashiwagi H, Pampori N. Integrin signalling: the platelet paradigm. Blood 1998; 91: 2645-2657.
22. Petrich BG, Marchese P, Ruggeri ZM, et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. JEM 2007; 204: 3103-3111.
23. Azam M, Andrabi SS, Sahr KE, et al. Disruption of the mouse μ-calpain gene reveals an essential role in platelet function. Molec Cell Biol 2001; 21: 2213-2220.
24. Hayashi M, Suzuki H, Kawashima S, et al. The behavior of calpain-generated Nand C-terminal fragments of talin in integrin-mediated signalling pathways. Arch Biochem Biophys 1999; 371: 133-141.
25. Schoenwaelder SM, Yuan Y, Cooray P, et al. Calpain cleavage of focal adhesion proteins regulates the cytoskeletal attachment of integrin alphaIIbbeta 3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin clots. J Biol Chem 1997; 272: 1694-1702.
26. Yan B, Calderwood DA, Yaspan B, et al. Calpain cleavage promotes talin binding to the β3 integrin cytoplasmic domain. J Biol Chem 2001; 276: 2864-2870.
27. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Ann Rev Pharmacol Toxicol 2007; 47: 211-242.
28. Moshal KS, Tipparaju SM, Vacek TP, et al. Mitochandrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am JPhysiol Heart Circ Physiol 2008; 295: H890-H897.
29. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opinion in Cell Biol 2001; 13: 534-540.
30. Shapiro D, Senior RM. Matrix Metalloproteinase. Matrix degradation and more. AM J Respir Cell Molec Biol 1999; 20: 1100-1102.
31. Duncan ME, Richardson JP, Murray GI, et al. Human matrix metalloproteinase-9: Activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. Eur J Biochem 1998; 258: 37-43.
32. Grant GA, Eisen AZ, Marmer BL, et al. The activation of human skin fibroblast procollagenase. Sequence identification of the major conversion products. J Biol Chem 1987; 262: 5886-5889.
33. Galis ZS, Kranzhofer R, Fenton, II JW, et al. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 483-489.
34. Tompa P, Buzder-Lantos P, Tantos A, et al. On the sequential determinants of calpain, cleavage. J Biol Chem 2004; 279: 20775-20785.
35. Rosenfeldt MT, Valentino M, Labruzzo S, et al. The organomecurial 4-aminophenylmercuric acetate, independent of matrix metalloproteinases induces dosedependent activation/inhibition of platelet aggregation. Thromb Haemost 2005; 93: 326-330.
36. Soslau G, Class R, Morgan DA, et al. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem 2001; 276: 21173-21183.
37. Soslau G, Pastorino MB, Morgan DA, et al. Herpes simplex virus replication and protein synthesis in a human blood-derived cell line. J Gen Virol 1987; 68: 2079-2092.
38. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
39. Soslau G, Wallace B, Vicente C, et al. Comparison of functional aspects of the coagulation cascade in human and sea turtle plasmas. Comp Biochem Physiol, Part B 2004; 138: 399-406.
40. Soslau G, Giles J. The loss of sialic acid and its prevention in stored human platelets. Thrombosis Res 1982; 26: 443-455.
41. Soslau G, Goldenberg SJ, Class R, et al. Differential activation and inhibition of human platelet thrombin receptors by structurally distinct α-, β-and γ-thrombin. Platelets 2004; 15: 155-166
42. Nieswandt B, Moser M, Pleines I, et al. Loss of talin 1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. JEM 2007; 204: 3113-3118.
43. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of TyK2, JAK2, and STAT3, and enhances agonist-induced aggregation in vitro. FEBS Lett 1995; 374: 48-52.
44. Chen K, Rondina MT, Weyrich AS. A sticky story for signal transducer and activator of transcription 3 in platelets. Circulation 2013; 127: 421-423.
45. Brodsky I, Siegel NH, Kahn SB, et al. Simultaneous fibrinogen and platelet survival with [75 Se] selenomethionine in man. Br J Haematol 1970; 18: 341-355.
46. Soslau G, Rybicki A. In vitro incorporation of fucose and methionine into human platelet proteins. Biochem Biophys Res Commun 1982; 109: 1256-1263.
47. Soslau G, Morgan DA, Jaffe JS, et al. Cytokine mRNA expression in human platelets and a megakaryocyte cell line and cytokine modulation of platelet function. Cytokine 1997; 9: 405-411.
48. Brass LF, Manning DR, Cichowski K, et al. Signalling through G proteins in platelets: to the integrins and beyond. Thromb Haemost 1997; 78: 5810589.
49. Yang J, Wu J, Jiang H, et al. Signalling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem 2002; 277: 46035-46042.
50. Zhang L, Brass LF, Manning DR. The Gq and G12 families of heterotrimeric G proteins report functional selectivity. Mol Pharmacol 2009; 75: 235-241.
51. Malinin NL, Plow EF, Byzova TV. Kindlins in FERM adhesion. Blood 2010; 115: 4011-4017.
52. Cecchetti L, Tolley ND, Mitchetti N, et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 118: 1903-1911.
53. Wrzyszcz A, Wozniak M. On the origin of matrix metalloproteinase-2 and-9 in blood platelets. Platelets 2012; 23: 467-474.
54. Weyrich AS, Schwertz H, Kraiss LW, Zimmerman GA. Protein synthesis by platelets: Historical and new perspectives. J Thromb Haemost 2009; 7: 241-246.
55. Schulze H, Ballmaier M, Welte K, et al. Thrombopoietin induces the generation of distinct Stat 1, Stat 3, Stat 5a and Stat 5b homo-and heterodimeric complexes with different kinetics in human platelets. Exp Hematol 2000; 28: 294-304.
56. Momi S, Falcinelli E, Giannini S, et al. Loss of matrix metalloproteinase-2 in platelets reduces arterial thrombosis in vivo. JEM 2009; 206: 2365-2379.